Canada's National Post chronicles some tough times in the country's biotech sector. Former high-flyers like QLT and Angiotech have seen their stocks come back to earth [1] after rocketing up. And this year the sector has done much worse in comparison to the much bigger biotech industry to the south [2]. Insiders lament that biotech is tough, with a long, hard road to travel from proof of concept to a marketable product. It's not all bad news, though. Theratechnologies [3] has done well this year.
- read the article [4] from the National Post
Related Articles:
Canada readies efforts to curtail drug traffic. Report [5]
QLT delays clinical program on Atrigel. Report [6]
QLT slashes spending as competition looms. Report [7]
Angiotech to acquire AMI in $785M buyout. Report [8]
Links:
[1] http://www.fiercebiotech.com/story/spotlight-rival-drug-drives-qlt-stock-lower/2005-07-20
[2] http://www.fiercebiotech.com/node/7490
[3] http://www.fiercebiotech.com/node/4989
[4] http://www.canada.com/nationalpost/financialpost/story.html?id=f881e114-3da7-47d5-909c-2cf47b184e4f&k=0
[5] http://www.fiercebiotech.com/story/canada-readies-efforts-to-curtail-drug-traffic/2005-06-24
[6] http://www.fiercebiotech.com/story/qlt-delays-clinical-program-on-atrigel/2006-05-19
[7] http://www.fiercebiotech.com/story/qlt-slashes-spending-as-competition-looms/2005-12-09
[8] http://www.fiercebiotech.com/story/angiotech-to-acquire-ami-in-785m-buyout/2006-02-01